丁苯酞联合阿托伐他汀钙治疗急性脑梗死患者的效果

Effects of Butylphthalide combined with Atorvastatin calcium on patients with acute cerebral infarction

目的:观察丁苯酞联合阿托伐他汀钙治疗急性脑梗死患者的效果。方法:选取2020年10月至2021年6月该院收治的90例急性脑梗死患者进行前瞻性研究,按照随机数字表法分为对照组和观察组各45例。两组均给予常规治疗,在此基础上对照组给予阿托伐他汀钙治疗,观察组在对照组基础上联合丁苯酞治疗。比较两组临床疗效,治疗前后血清学指标[基质金属蛋白酶-9(MMP-9)、神经元特异性烯醇化酶(NSE)、同型半胱氨酸(Hcy)、6-酮-前列腺素-F1a(6-k-PGF1a)]水平、神经功能[美国国立卫生研究院卒中量表(NIHSS)评分]和日常生活能力[Barthel指数(BI)],以及不良反应发生率。结果:观察组治疗总有效率为95.56%,高于对照组的75.56%,差异有统计学意义(P<0.05);治疗后,两组MMP-9、NSE、Hcy水平均低于治疗前,且观察组低于对照组,两组6-k-PGF1a水平均高于治疗前,且观察组高于对照组,差异有统计学意义(P<0.05);两组NIHSS评分均低于治疗前,且观察组低于对照组,两组BI评分均高于对照组,且观察组高于对照组,差异有统计学意义(P<0.05);观察组不良反应发生率为6.67%,低于对照组的26.67%,差异有统计学意义(P<0.05)。结论:丁苯酞联合阿托伐他汀钙治疗急性脑梗死患者可提高治疗总有效率和BI评分,改善血清学指标水平,以及降低NIHSS评分和不良反应发生率,效果优于单纯阿托伐他汀钙治疗。

Objective: To observe effects of Butylphthalide combined with Atorvastatin calcium on patients with acute cerebral infarction.Methods: 90 patients with acute cerebral infarction treated in our hospital from October 2020 to June 2021 were selected for the prospective study,and were divided into control group and observation group according to the random number table method, 45 cases in each group. Both groups were given conventional treatment. On this basis, the control group was treated with Atorvastatin calcium tablets, while the observation group was treated with Butylphthalide on the basis of that of the control group. The clinical efficacy, the serological index levels before and after the treatment [matrix metalloproteinase-9(MMP-9), neuron-specific enolase(NSE), homocysteine(Hcy), 6-keto-prostaglandin-F1a(6-k-PGF1a)], the neurological function [national institutes of health stroke scale(NIHSS) score], the activities of daily living [Barthel Index(BI)], and the incidence of adverse events were compared between the two groups. Results: The total effective rate of the observation group was 95.56%, which was higher than 75.56% of the control group, and the difference was statistically significant(P<0.05). After the treatment, the levels of MMP-9, NSE and Hcy in the two groups were lower than those before the treatment, and those of the observation group were lower than those of the control group;the levels of 6-k-PGF1a in the two groups were higher than those before the treatment, and that of the observation group was higher than that of the control group;and the differences were statistically significant(P<0.05). The NIHSS scores of the two groups were lower than those before the treatment, and that of the observation group was lower than that of the control group;the BI scores of the two groups were higher than the control group, and that of the observation group was higher than that of the control group;and the differences were statistically significant(P<0.05). Further, the incidence of adverse reactions in the observation group was 6.67%, which was lower than 26.67% in the control group, and the difference was statistically significant(P<0.05). Conclusions: Butylphthalide combined with Atorvastatin calcium in the treatment of the patients with acute cerebral infarction can improve the total effective rate and the BI score, improve the levels of serological indexes, and reduce the NIHSS score and the incidence of adverse reactions. Moreover, it is superior to single Atorvastatin calcium.